Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the Best Performing Long Term Stocks According to Analysts. On September 10, Corcept Therapeutics Incorporated (NASDAQ:CORT) announced that the FDA has accepted its new drug application for Relacorilant to treat platinum-resistant ovarian cancer. Management noted that the FDA has set a decision date of July 11, 2026, under the Prescription Drug User Fee Act. The application acceptance is based on the positive results from the Phase 3 ROSELLA trial ...